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a b s t r a c t
Human rhinoviruses of the RV-C species are recently discovered pathogens with greater clinical
signiﬁcance than isolates in the RV-AþB species. The RV-C cannot be propagated in typical culture
systems; so much of the virology is necessarily derivative, relying on comparative genomics, relative to
the better studied RV-AþB. We developed a bioinformatics-based structural model for a C15 isolate.
The model showed the VP1–3 capsid proteins retain their fundamental cores relative to the RV-AþB, but
conserved, internal RV-C residues affect the shape and charge of the VP1 hydrophobic pocket that
confers antiviral drug susceptibility. When predictions of the model were tested in organ cultures or
ALI systems with recombinant C15 virus, there was a resistance to capsid-binding drugs, including
pleconaril, BTA-188, WIN56291, WIN52035 and WIN52084. Unique to all RV-C, the model predicts
conserved amino acids within the pocket and capsid surface pore leading to the pocket may correlate
with this activity.
& 2013 Elsevier Inc. All rights reserved.
1. Introduction
The human rhinoviruses (RV) are positive sense RNA viruses in
the Enterovirus genus of the Picornaviridae family (Palmenberg et al.,
2009). They are the most frequent causative agents of the “common
cold” and responsible for millions of lost personnel hours in the
workplace each year. The best studied isolates belong to the RV-A and
RV-B species, where they are binned together if they share greater
than 75% nucleotide identity (88% amino acid identity) in the VP1
region of their polyproteins. Each species further divides its isolates
into multiple numbered genotypes. Originally, 100 types from
clinical panels archived by the American Type Culture Collection were
indexed after assessment of antigenic crossreactivity or serotyping
in rabbits. RV-A87 was subsequently reassigned to the Enterovirus
D (EV-D68) after reevaluation of genetic, immunogenic and receptor
properties (Savolainen et al., 2002). Common to the original RV-A
(74 serotypes) and RV-B (25 serotypes) is the use of ICAM-1 or LDLR
for cell attachment and entry (Vlasak et al., 2005). They are labile at
low pH (o5), and grow predominantly in sinus and upper airway
tissues (for reviews, see (Bochkov and Gern, 2012; Ashraf et al., 2013)).
Because of their medical and economic importance, considerable
resources have been expended developing therapeutics against the
RV-AþB. The ubiquitous nature of these viruses and the many
serotypes, preclude the practical use of vaccines. Directed drugs that
target protein elements in the RV replication cycle (e.g. rupintrivir),
can be effective (Binford et al., 2007). But the preferred strategy is to
target the virus before infection, usually by exploiting unique “pocket”
features characteristic of all enterovirus virions. The RV capsids are
icosahedral (pseudo T¼3), composed of 60 copies each of four
structural proteins, VP1, VP2, VP3 and VP4. The three largest proteins,
VP1–3, assume similar 8-stranded, anti-parallel β-barrel motifs,
despite being formed from very different sequences (Fig. 1). Protomer
subunits containing mature copies of VP1–4 spontaneously self-
assemble into pentamers with the VP1 proteins assuming symmetry
around the 5-fold axes. When the pentamers coalesce into particles,
encapsidating the genome RNA, the VP2–3 proteins alternate around
the 3-fold and 2-fold axes (Fig. 1A). A deep groove within each
protomer, formed where VP1–3 abut, creates a contiguous “canyon”
circling each pentamer (Fig. 1B). The canyon topography is character-
istic of all enteroviruses, and marks the thinnest portion of the capsid
shell. The “north” (5-fold) and “south” (2-fold) walls of the canyon
(Fig. 1C) are lined with residues that confer receptor recognition and
type-speciﬁc immunogenicity (Arnold and Rossmann, 1990).
When the 99 historical RV-AþB types were tested for sensi-
tivity against a panel of antiviral capsid-binding therapeutics they
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were found to subdivide, roughly along species lines, into two
experimental groups (Andries et al., 1990). The structures of 28
virus-drug complexes have been determined to atomic resolution
(Suppl. Table S1). The Group-1 viruses (predominantly RV-B) have
long, narrow pockets interior to their VP1 proteins, which accom-
modate matching long chain hydrophobic drugs like WIN52084
(W84). The Group-2 viruses (most RV-A) have shorter, wider VP1
hydrophobic pockets, and therefore accept an alternate cohort of
drugs, like R61837 (JEN). Each determined drug-virus structure
shows a pore-like opening connecting each VP1 pocket to the
deepest portions of the canyon, providing an entry port for the
relevant drug (Fig. 1B). Native RV-AþB in the absence of drugs,
have “pocket factors”, commonly modeled as sphingosine, in same
interior VP1 locations. The intrinsic occupancy of these factors
contributes to capsid stability (Oliveira et al., 1993). Displacement
of the native factors with efﬁcacious drugs prevents a required
VP1 transition during the uncoating process, making such drugs
inhibitory to infection. Compounds that exploit this mechanism
and bind both Group pockets have shown clinical promise on a
range of RV. For example, during Phase 3 evaluations, pleconaril
(WIN63843) shortened the duration of the common cold and
reduced the window of virus shedding. Despite this efﬁcacy, the
FDA disapproved pleconaril for over-the-counter use, citing con-
cerns about interference with the metabolic pathways of other
drugs (Hayden et al., 2003). A newer analog, BTA-188, is reportedly
more effective in reducing RV infections for many laboratory and
clinical strains (Barnard et al., 2004).
While a “cure” for the common cold might have seemed in the
ofﬁng from this work, the discovery in 2006 of a completely new
RV species, put optimism on hold. The RV-C are clearly rhino-
viruses, but unlike RV-AþB, they are not readily propagated in
typical cell culture systems (Bochkov et al., 2011). The currently
recognized 51 types of RV-C were detected and characterized by
direct sequencing from patient efﬂuents. As with the RV-AþB,
each RV-C type includes those isolates whose VP1 sequences
exceed 87% pairwise identity at the nucleotide level (Simmonds
et al., 2010; McIntyre et al., 2013). The RV-C have special clinical
relevance since it is now recognized these strains are associated
with up to half of infections in young children (Bochkov et al.,
2011). They grow readily in both the lower and upper airways and
tolerate higher growth temperatures in culture (Ashraf et al.,
2013). Moreover, the RV-C use cell receptors that are not common
to the RV-AþB (Bochkov et al., 2011). Unfortunately, these
receptors are apparently lost, whenever primary tissue snippets
are transitioned to undifferentiated monolayers. RV-C can be
grown in mucosal organ cultures, but this technique requires the
availability of primary human donor samples (Bochkov et al.,
2011). Parallel work with differentiated sinus or bronchial epithe-
lial cells at air–liquid interface (ALI) is promising (Ashraf et al.,
2013; Hao et al., 2012), but neither technique has yet produced
enough virus for extensive biological studies. Instead, RV-C infor-
mation relies heavily on comparative sequence analysis to max-
imize data from limited experimental samples.
Current computational tools include a deep alignment of full-
genome datasets for 4350 RV-AþBþC isolates. It was nucleated
by superimposition of determined capsid structures for multiple
RV-AþB, then extended to the RV-C with Markov-based proﬁle ﬁts
(Palmenberg et al., 2009). Combined with the RV-AþB structures,
the alignment helped to develop a high resolution 3D model for
C15 (Basta et al., this issue), an isolate which has been cloned into
cDNA, and tested for biological activity in mucosal and ALI cultures
(Ashraf et al., 2013; Bochkov et al., 2011). The new model displays
an altered surface topography for all RV-C, accounting for differ-
ential receptor use and diverse immunogenicity (Basta et al., this
issue). It also shows the essential Cα backbone of the RV-C VP1 β-
core that marks the capsid drug-binding pocket is superimposable
on the RV-AþB, regardless of whether the model was tweaked by
Group 1 (e.g. B14) or Group-2 (e.g. A16) structures. While this was
reassuring in terms of model veracity, the outcome was puzzling
in terms of biology, because in preliminary studies (below),
recombinant C15 virus was known to behave somewhat differ-
ently from Group-1 or Group-2 RV.
The lack of primary organ cultures and inconsistencies among
donor samples make tests against the RV-C difﬁcult. We reported
that WIN56291 (W91), a short chain (Group-2) compound, was
efﬁcacious against C15 when tested in sinus organ cultures
(Bochkov et al., 2011), but it was not clear whether those results
would be common to the more reliable ALI systems (Ashraf et al.,
2013). Another study reported that the usually-more-potent
pleconaril was only weakly effective against C15 when tested
in ALI cultures (Hao et al., 2012), although it readily inhibited A16
controls. Therefore, it is indeterminate whether the RV-C are indeed
Fig. 1. RV-C15 capsid model. (A) The C15 model with VP1 (blue), VP2 (green) and VP3 (red) proteins, around 5-fold, 2-fold and 3-fold axes of symmetry (Basta et al., this
issue). The short VP4 protein (yellow) is internal. (B) A triangular crystallographic (PDB) subunit orients the VP1þVP2 from one biological subunit, with VP3 from the
adjacent, counterclockwise unit. The hydrophobic drug binding pocket extends from a pore at the base of the canyon into the VP1 central core. (C) The VP1–3 proteins have
similar 8-stranded β-barrels with extended connecting loops. The canyon is a depression in the surface topography, ringing the 5-fold. The north and south walls are
landmark features. Pleconaril (gray spheres) is modeled into the VP1 pocket. Figure is taken from Hadﬁeld et al. (1995).
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susceptible to those capsid-binding drugs categorized by existing
Groups, or if they represent a new category with a different pocket
efﬁcacy. To gain more insight, the C15 capsid model was re-probed
against all known RV PDB datasets, looking for structural inconsis-
tencies and/or conserved sequences that might explain observed drug
reactivity. Parallel experiments in mucosal organ culture and ALI
cultures re-tested the efﬁcacy of W91, as well as W84, WIN52035
(W35), pleconaril and BTA-188, added or preloaded into C15 and A16
virions. The model, sequences and mutagenesis experiments suggest
there are multiple residues, including those at the entrance to the VP1
pore, that co-vary among all RV-C and contribute to a novel pocket
environment. These “Group-3” pockets could explainwhy all RV-C are
probably refractive to strategies with the current antiviral drugs.
2. Results and discussion
2.1. C15 drug susceptibility
Pleconaril and BTA-188 are effective against many RV-AþB
types. One study reported that BTA-188 inhibited 75% (of 56)
tested strains, including A16 with an MIC50 of 8 nM and B14
with MIC50 of 68 nM (Barnard et al., 2004). Pleconaril was
reported effective on 93% (of 101) RV-AþB, with an EC50 of
0.59 μM for A16, and 0.16 μM for B14 (Ledford et al., 2004). Drug
testing for the RV-C is more difﬁcult. Studies have described
recombinant C15 as resistant to pleconaril (Hao et al., 2012), but
susceptible to a related compound, W91 (Bochkov et al., 2011).
Neither report did extensive testing because the RV-C can only be
titered by qRT-PCR, and the yield in organ cultures (Bochkov et al.,
2011) or ALI (Ashraf et al., 2013; Hao et al., 2012) is relatively low.
For organ cultures particularly, variability among donors creates
signiﬁcant reproducibility issues (Bochkov et al., 2011) as well as a
paucity of viable samples for proper controls. In new attempts
with this technique, W84 and W35 were tried in sinus organ
culture against A1, A16 and C15. Both drugs seemed partially
effective against A1 (n¼1), and the yield of A16 also showed some
reduction with W84. But neither reduced the replication of C15
(Suppl. Fig. S1A).
The inherent inconsistencies with organ cultures warranted a
change to human bronchial (HBE) or sinus (HSE) epithelial ALI
cultures derived from primary tissue snippets. While again, cell
expansion is limited, with successful cultures, the method has less
variability and more samples can be tested simultaneously. Pre-
experiments with WisL cells and A16 determined the lowest
concentration of drugs that prevented cytopathatic effect (CPE) and
virus replication without overt toxicity (e.g. rounding or lifting from
the plate). For pleconaril and BTA-188, those were 10 μg/ml and
2 μg/ml, respectively (Suppl. Fig. S1B). When A16 and C15 were
incubated with these drugs, then titered in HSE-ALI cultures (Fig. 2A),
the controls showed typical virus replication as evidenced by the 1–
2 Log increase in genome signal (RNA Copies) between 4 h (gray
bars) and 24 h (blue/red bars) relative to a 0-time binding control
(white bar). Pleconaril or BTA-188 signiﬁcantly reduced A16 ampli-
ﬁcation (blue bars), but neither drug had the same effect on C15 (red
bars). The same result was obtained with a subsequent, independent
ALI culture (Fig. 2B). Whether the drugs were present or not, C15
bound equivalently to the cultured cells, established productive
infections and ampliﬁed normal progeny numbers. In parallel experi-
ments, C15 was also resistant to W91 at a concentration (2 μg/ml)
that reduced A16 growth by 1.3 Log (Fig. 2C). The previous partial
susceptibility to this compound in organ culture could not be
repeated in ALI culture. It is possible the reported phenomenon
was unique to virus growth in that particular donor organ sample. In
short, throughout multiple attempts, none of the 5 tested capsid-
binding drugs had efﬁcacy against C15.
Fig. 2. Drug tests. (A) Recombinant A16 and C15 were titered for growth in HSE-ALI cultures in the presence of pleconaril or BTA-188. Colored bars (blue, red) are from
samples harvested after 24 h PI. Gray bars were harvested after 4 h PI. White bars are 0-time binding controls. (B) Similar to A, this series used an independent HSE-ALI
culture. (C) Similar to A, virus samples incubated with W91 were titrated for growth in HSE-ALI cultures. (D) Recombinant A16 and C15 transcripts were transfected into
HeLa cells with (or without) BTA-188. After 24 h, virus was harvested and titered by qRT-PCR. (E) Output virus from D was infected into HBE-ALI culture as in A, except no
additional drug was added during this phase. In all panels, qRT-PCR values (RNA copies) were determined in duplicate. Experimental repeats are indicated (n). Bars indicate
average error from n exps.
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2.2. Capsid-drugs ﬁt C15 models
The activities of enterovirus capsid-binding drugs have been
reviewed extensively (e.g. Shih et al., (2004; Rossmann, 1994).
When such drugs intercalate into the VP1 hydrophobic pocket,
they can deform the ﬂoor of the canyon to an extent that receptor
binding and attachment is inhibited (e.g. B14 and pleconaril)
(Pevear et al., 1989). Alternatively, they may enter the pocket with
minimum canyon deformation, but prevent required VP1 transi-
tions for entry and uncoating (e.g. A1 and W56) (Rossmann, 1994).
Assuming biostability is not an issue, drug failure comes down to
one of three mechanisms. The selected drug might be a poor steric
ﬁt for a given pocket, and rejected. The drug might ﬁt the pocket
but fail to prevent required VP1 changes. Or, the drug might be
excluded from the pocket altogether, either because it cannot
enter, or cannot displace putative resident pocket factors.
By deﬁnition, none of the determined RV-AþB structures
exhibit steric clashes between the VP1 proteins and their ligands.
These would have been resolved at coordinate deposition. Steric
considerations that might explain C15 drug resistance were
explored with bioinformatics and the new capsid models. Since
output coordinates can adjust slightly, dependent on precise
template selection, four C15 VP1 models were created by I-
TASSER (Basta et al., this issue), using independent A16 and B14
determined structures that did or did not include bound pleno-
naril. An additional model was computed on the full I-TASSER
database, containing 31 RV ﬁles and 29 EV ﬁles. Each model was
asked to extract from these structures, the subset of
10 best ligand ﬁts for that C15 VP1 conformation. Collectively
they identiﬁed 12 synthetic compounds covering both Group-1
and Group-2 capsid-binding drugs, and three natural compounds,
myristate, succinate and lauric acid, which were co-crystalized as
natural ligands (Suppl. Table S2). For each C15 dataset, the
identiﬁed ligands were superimposed into chimeric PDB ﬁles then
assessed in MacPyMOL for steric clashes. A negative “C15 Fit” was
deﬁned as any single VP1 atom lying closer than 0.35 Å to a ligand
atom. W35 and W91 were included for completeness although
they were not directly selected by I-TASSER. The BTA-188 structure
(in RV-A2) was a personal communication (Biota). As summarized
in Table 1, many of these drugs (or natural ligands) were excellent
ﬁts for the C15 pocket. Pleconaril and BTA-188 in particular,
usually matched the cavity with ease (e.g. Fig. 3B). Indeed, all 5
C15 models selected pleconaril as a preferred ligand, sometimes
choosing multiple related structures (e.g. 1c8m and 1nd3) from
the database.
“Fit” was assessed negatively if even a single atom overlapped,
but in fact, every determined compound in the RV database was
identiﬁed at least once by an I-TASSER model, as a potential ligand
for C15. Of the 41 observed clashes, most involved a limited subset
of residues (Fig. 3A, Table 1). Only 1 of these (pleconaril and
Met204) originated from a ligand resolved as part of an RV-A
structure (1nd3). Invariably, the conﬂicting atoms were contrib-
uted by a B14-bound drug, a suboptimal template for C15 model-
ing (Basta et al., this issue). All conﬂict locations were peripheral to
the core of the C15 β-barrel, and scattered throughout its length
(Fig. 3A). W84, W56, W8R, were selected several times among the
highest ranking ligands, even though they showed the most
frequent (2–3) steric clashes. Perhaps not surprising, these same
(Group-1) drugs have the longest chain lengths (Suppl. Table S1).
They can be made to ﬁt perfectly into C15, if allowed only slightly
less rigid superimposition parameters (not shown). Indeed, any of
the observed conﬂicts could probably be resolved easily by minor
bond rotations (if permitted). Basically, the full modeling exercise
was unable to identify any single, overt steric impediment that
might prevent the well-studied cohort of capsid drugs from
intercalating into the C15 VP1 pocket. In terms of physical
constraint alone, the C15 model(s) do not immediately predict
resistance, either to Group-1 or Group-2 drugs.
2.3. Drug pocket environment
The pocket residues important for A16 and B14 drug binding,
especially for pleconaril, are well described (Zhang et al., 2004;
Ledford et al., 2005). An inclusive contact list within the VP1
β-core was generated with Endscript (Gouet and Courcelle, 2002),
by evaluating the 28 RV-AþB structures co-crystalized with drugs
and returning every residue within 4 Å of any drug, in any virus.
The 43 C15-drug models were scored in parallel. The tabulation,
summarized by WebLogo (Fig. 4), shows species variation and
frequency according to the deep RV alignments, for every
putatively-involved amino acid. The C15 positions identiﬁed by
PyMOL as possible steric clashes are designated in purple. Below
each position, a stacked graph records the number of structures
(RV-A, blue, Nmax¼7; RV-B, red Nmax¼22) or models (RV-C, light
green, Nmax¼43), placing that residue within 4 Å of any drug.
Deﬁned, pleconaril-reactive residues (Zhang et al., 2004) are bold-
faced. The RV isolates with Group-1 and Group-2 drug reactivity
correlate roughly with the B and A species, respectively (see
Section Materials and methods).
How do these pockets differ? The 36 proﬁled sites divide into
obvious categories. The ﬁrst (Category-1) includes about half the
residues, marking the positions least frequently identiﬁed by the
4 Å proximity criterion. If only 1–10 models or structures returned
these sites (Nmax¼72), they are probably not key drug resistance
determinants, even though all of them must certainly contribute
to the overall RV-C pocket environment. The remainder had
proximity thresholds that were returned by at least 11 models or
structures. These include, among others, all site analogs previously
associated with pleconaril interactions (bold numbers). This
cohort itself subdivides into those where the residues are con-
served among all RV-AþBþC (Category-2), or where conservation
Table 1
Summary of C15 Drug/Model Conﬂicts.
Drug/
liganda
Returned C15
models without
steric clashesb
Returned C15
models with
steric clashesc
Conﬂicting
C15 VP1 residuesd
BTA-188 1 0 None
Pleconaril 8 2 Phe132(1), Met204(1)
W91 1 0 None
W54 1 0 None
W84 0 6 Phe96(6), Asn202(5),
Met204(6)
S57 1 1 Phe132(1)
W01 2 0 None
W03 3 0 None
W35 1 0 None
W71 2 0 None
J77 1 0 None
W56 1 4 Phe132(3), Met204(4)
W8R 0 2 Phe96(2), Met180(2),
Met204(2)
SD8 1 0 None
JEN 1 4 Met116(1), Tyr178(3),
Met204(3), Leu207(2)
Myristate 5 0 None
Lauric
Acid
3 0 None
Succinate 2 0 None
a Ligands selected by I-TASSER for any C15 model (Suppl. Table S1).
b Number of models returned by I-TASSER with no steric clashes (Suppl.
Table S1, “C15 Fit” is “Yes”).
c Number of models returned by I-TASSER with 1 or more clashes.
d C15 VP1 residues with clashes (observations).
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is between the RV-C and either the RV-A or RV-B (Category-3), or
where the dominant RV-C sequence(s) is unique (Category-4). The
RV common sites (Category-2) include Ile94, Phe114, Met131, Ser155,
Phe167, Tyr178, Asn202 and Met204. Category-3 includes Gln97, Val/
Ile118, Phe/Tyr132, Pro154, Val156, Met180, and Leu207. Collectively,
Categories 2þ3 contain 5 of the 7 residues with incidents of
(putative) steric clashes (Tyr178, Met180, Asn202, Met204, and
Leu207). Again, these modeled clashes are unlikely to be critical
determinants of RV-C drug resistance, because the same residues
are frequently displayed equivalently in the pockets of many
susceptible RV-AþB. The same could be said for virtually all of
the Category-2þ3 residues, in that these sequences, shared freely
among at least 2 species, do not interfere with the deﬁned Group-
1 or Group-2 drugs.
Residue Phe/Tyr132 is an exception, however. In 2005, as part of
a pleconaril study, Ledford et al. (2005) noted that not all RV-AþB
were susceptible to this drug. B4, B5, B42, B84, B93, B97 and B99
are resistant. When they compared the relative sequences of 25
key B14 VP1 residues, it was noticed that susceptible viruses
invariably displayed Tyr152 and Val191 in their drug pockets, while
the resistant viruses had Phe and Leu at the same positions
(orange). Between B14 (susceptible), and B5 or B42 (resistant),
these were the only sequence changes in the pocket (or the pore).
Recombinant exchange of these residues in a B14 context, reversed
pleconaril susceptibility. The study concluded that Leu191 was the
“major driver” of reduced susceptibility, but the effect was most
profound if both sites were changed simultaneously.
Among the RV-C, none, including C15, has the B14 susceptible
proﬁle for these 2 residues. The B14 Tyr152 is equivalent to C15
Phe132. The B14 Val191 is equivalent to C15 Thr172, a Category-4
position, marking it as unique to the RV-C. Unfortunately, the
Ledford study never deﬁned why these particular residues con-
ferred apparent resistance. The A16 analog, Tyr144, undergoes the
largest displacement in the pocket when pleconaril binds this virus
(Zhang et al., 2004). The Leu184 (in A16) or Val191 (in B14) localize
nearby to the same Ring B segment of the drug (Zhang et al., 2004)
(Fig. 3C and D). Not only do the RV-C lack a susceptibility proﬁle at
these sites, they have 4 additional drug-proximal residues in
Category-4 that again, mark them as unique. The C15 Phe96, Met/
Leu116, Ile130 and Ile169 positions are rarely (or never) shared with
the other species. The RV-C conserve these selections at 93%, 57/
43%, 93% and 100%, respectively. In the various C15 models, the
pocket ﬂoor (Fig. 3A and B), displaying Phe96 and Met116 caused
occasional steric clashes with the longest (W56, W8R, W84) or
fattest (JEN) drugs (Table 1), although as mentioned above, only a
few of the drugs and a few of the models recorded such conﬂicts.
2.4. Drug pocket pores
For capsid drugs to be effective, they must traverse a narrow
pore at the base of the canyon into the VP1 core. The opening is
a clear, resolved feature in all B14 structures (Fig. 5B). Sited in the
very deepest portion of the canyon, the pore is immediately
adjacent to the COOH end of VP3 (in red, Fig. 5A–C). Several
participating B14 residues, including Asn105, Asn219 and His220
have been described with natural mutations conferring drug
resistance or drug selectivity (Hadﬁeld et al., 1995; Kolatkar
et al., 1999). The observed mutations did not prohibit drug entry,
but instead, partially compensated for drug-induced VP1 changes
by providing tighter receptor interactions in the overlapping
ICAM-1 footprint (Hadﬁeld et al., 1995). The pore contributions
are not as well studied for A16, but again, every resolved structure
shows a distinct opening in the same location (Fig. 5A). From the
proper angle, the tails of VP1-embedded drugs, pleconaril in these
illustrations (dark blue) can be glimpsed through the A16 and B14
holes. To better describe these pores, all canyon residues within
7–9 Å of these tails, were compiled (MacPyMOL), then queried
within the sequence alignment for analogs among the species. In
the RV-C, 5 of the 9 residues showed Category-2 or Category-3
conservation, including the 3 mutant-deﬁned B14 locations (C15)
Asn95, Asn202, Asp203, as well as Ile94 and Ser99 (Fig. 4D). The other
residues, Glu93, Lys245, Tyr246 and Ser247 were Category-4, and
Fig. 3. Key RV residues and pleconaril. (A) Pleconaril (spheres) modeled in the drug pocket of C15 highlights the distribution of any potential residue that could cause a steric
clash with any modeled drug as per Table 1 (purple). Location of Phe132 and Thr172, the Ledford et al. (2005) residues that confer resistance to B14 are highlighted in orange
(all panels). (B) C15 model, (C) A16 (1ncr) and (D) B15 (1ncq) with pleconaril are shown as cutaways through the drug pocket. The 5-fold is to the right. The 2-fold, canyon
and entry pore (not always visible here) are at the upper left of the pockets.
H.A. Basta et al. / Virology 448 (2014) 82–9086
showed higher diversity within and between species. The RV-C
do not use the same ICAM-1 footprint as the RV-AþB (Bochkov
et al., 2011), so some diversity was expected here. What was not
expected, was the visible absence of any discernible opening that
even resembled a pore in the C15 model. In fact, none of the
models, no matter which PDB templates reﬁned them, showed an
opening into the VP1 core at this locale (e.g. Fig. 4C). The change in
mass, blocking the opening was contributed by several residues,
but primarily by Tyr246 (purple), conserved as Tyr or Phe in 88% of
the RV-C. Every RV-B encodes Gly here (B14 267, 100%), while the
RV-A have His (A16 260, 68%). Sterically, C15 Tyr246 is reasonably
conﬁned to this orientation as are its surrounding neighbors. If this
model's predictions were true for real virions, drug entry might be
slowed or even precluded by the tighter passageway. Conceivably
though, an appropriately effective drug (pleconaril is modeled
here) might ﬁnd an alternate route elsewhere in the canyon
into the VP1 core, or even persevere here by wiggling through
tenaciously, despite the altered sequences.
2.5. C15 grown with drug
During sample preparation for crystallography, it is common to
diffuse capsid-binding drugs into preformed virus arrays or to co-
crystalize the materials. Should this not achieve sufﬁcient occu-
pancy for diffraction, the virus can be grown in the presence of the
drug and then crystallized (Zhang et al., 2004). If capsid drugs
were prevented from entering C15 when mixed with virus, it
seemed reasonable that the impediment(s) might be resolved
through co-culture conditions. Recombinant transcripts for A16
and C15 were transfected into HeLa cells in the presence or
absence of BTA-188 then incubated for 24 h. After cell lysis and
treatment with RNAse, qRT-PCR showed both preparations had
produced stable virions. The progeny outputs (n¼6) were similar
whether or not the drug was present (Fig. 2D). But when the
derived lysates were tested for infectivity to ALI cultures, only the
pre-treated A16 samples were unable to replicate (Fig. 2E). Expo-
sure to BT-188, even during the packaging of C15 progeny, did not
inhibit their subsequent growth potential.
2.6. Predictions for RV-C drug reactivity
All of the Category-4 analogs in pockets and pores of the RV-AþB,
as well as C15 Phe132, are deﬁned, important players in drug selection
or binding, especially for pleconaril. The collective sequence changes,
notably those involving polar residues (e.g. C15 Met118 vs. B14 Ser128,
or C15 Thr172 vs. B14 Val191), and size changes (e.g. C14 Phe96 for B14
Leu106, or C15 Ile169 for B14 Val188, C15 Tyr256 for B14 Gly267) must
surely change the underlying character of the RV-C VP1, let alone its
structural ﬂexibility. Short of an experimental C15 structure with an
active drug, it is impossible to anticipate the relative contributions of
these residues to the broader question of drug resistance. The
observed Category-2þ3 residues are not wholly common or pre-
dictive of Group-1 or Group-2 isolates either. Instead, the sequence
modeling, residue comparisons, and obviously the drug tests them-
selves, suggest the RV-C should be generalized with novel “Group-3”
reactivity. Without labeled drug tracers, which are beyond the scope
of this study, it cannot even be determined whether BTA-188 (and
presumably pleconaril) actually intercalates into the C15 pockets.
Possibly these drugs are indeed bound, but their inclusion is simply
irrelevant to this virus life cycle. The RV-C do not use ICAM-1 or LDLR
receptors which probe deeply to the canyon ﬂoor and are therefore
sensitive to VP1 deformations (Rossmann, 1994). Alternatively, the
Group-3 pockets may just be more strongly dependent on the
presence of the native pocket factor(s) than the RV-AþB. If the RV-
C preferentially incorporated and retained these factors, the essential,
capsid-stabilizing properties would be relinquished only reluctantly
and infrequently, to any drug replacement, even during protomer
assembly. A putatively narrower or absent pore and the lack of
reactivity even when C15 was grown in the presence of BTA-188 are
consistent with this interpretation.
3. Materials and methods
3.1. Sequences and alignment
Reﬁned alignments (337 seqs) of complete RV genome sequences
are based on foundation superimposition of determined protein
structures as described (Palmenberg et al., 2009; Basta et al., this
issue). A translated polyprotein alignment with species, type and
Fig. 4. Drug pocket residues. WebLogo depictions (Crooks et al., 2004) for the
RV-AþBþC were tabulated for all VP1 residues measured within 4 Å of any
determined or modeled ligand as deﬁned by Endscript (Section Materials and
methods). The sequence set was the reﬁned genome alignment. The graphs show
the number of determined structures (RV-B in blue, RV-A in red) and RV-C models
(green) that placed that residue near a ligand. Position numbers are those for native
A16, B14 and C15 VP1 sequences. Published interactions with pleconaril (Zhang
et al., 2004) are shown in bold. Residues identiﬁed in Table 1 with potential steric
clashes are in purple. The 2 pleconaril-resistant locations, identiﬁed by Ledford
et al. (2005) are highlighted in orange. The category value assigned to each position
is described in Section Results and Discussion.
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accession numbers are available in fasta and meg formats from
http://virology.wisc.edu/acp/aligns/. The set includes RV-A (77 types,
203 seqs), RV-B (25 types, 69 seqs), RV-C (30 types, 65 seqs), and EV
outgroups (4 species, 10 seqs). Current RV nomenclature designates
the species letter (A, B or C), and type number (e.g. A16). Strain
designations are unique to each accession number. Group-1 and
Group-2 drug speciﬁcities are as deﬁned (Andries et al., 1990). Brieﬂy,
Group-1 includes all RV-B plus A8, A13, A32, A43, A45, A54, and A95.
Group-2 includes all remaining RV-A except A100–103, which like
the RV-C were not tested in the original study. The amino acid
numbering system is for C15 protein VP1 (GU219984), unless
otherwise speciﬁed. Analogous residues for A16 (L24917) and B14
(L05355) in the same alignment column are referred to with their
native (ungapped) sequence designations.
3.2. Molecular modeling
An I-TASSER model, with output PDB ﬁle, was predicted for the
capsid of C15. It is primarily based on the structure of A16 (1aym)
as has been described (Basta et al., this issue). Reﬁned, protomer
and virion coordinates (hrvc) are available from VIPERdb (http://
viperdb.scripps.edu/). Subunit illustrations were rendered in
MacPyMOL The PyMOL Molecular Graphics System (2008). UCSF
Chimera (Pettersen et al., 2004) created full capsid structures and
pentameric assemblies from protomer ﬁles. The PDB entries for
enteroviruses (CB3, PV3) and RV-AþB with antiviral drugs or
identiﬁed pocket factors resolved within their VP1 pockets, are
summarized in Suppl. Table 1. Drug names, abbreviations, refer-
ences and published MIC50 are indicated. Each listed set of C15
coordinates was generated by I-TASSER then submitted online
(http://endscript.ibcp.fr/) to Endscript (Gouet and Courcelle, 2002).
The Crystallography and NMR System (CNS) module within this
program identiﬁed lists of residues within 4 Å of any bound
compounds for the RV-AþB (Fig. 5), including (53 ) at least
one iteration of every crystallized drug or pocket factor ligand.
Additional evaluations extracted list(s) of C15 residues within 4 Å
of any (putative) ligands, should the chimeric model(s) be repre-
sentative of analogous interactions (see Suppl. Table S2).
3.3. Viruses
Recombinant A16 was produced in WisL cells (Lee et al., 1995).
When required, titration was by plaque assay on HeLa cells. C15
virus was prepared by reverse genetics, transfecting full-length
Fig. 5. Drug pocket pores. (A) A16 (1aym), (B) B14 (4rhv), and (C) C15 (model) space-ﬁlling surfaces show VP1 residues at the base of the canyon, guarding the entrance to
the drug-binding pockets. The COOH tail of VP3 (red) and pleconaril (dark blue) orient these ﬁgures clockwise, 901 relative to Fig. 1, with the 5-fold to the right, and 2-fold to
the left. (D) WebLogo depictions (Crooks et al., 2004) for the RV-AþBþC were tabulated for these residues. The putatively obstructive C15 Tyr246 and its analogs are
highlighted in purple.
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RNA transcripts into HeLa or WisL cells, then purifying and
concentrating the progeny as described (Bochkov et al., 2011).
3.4. Drugs
WIN56291, WIN52035 and WIN52084 were provided by Dr. Wai-
Ming Lee. Pleconaril and BTA-188 were provided by BIOTA (Australia).
Working concentrations were prepared fresh for each experiment.
3.5. Drug standardization
Pleconaril, BTA-188 and W91 were evaluated for minimum
inhibitory concentrations and toxicity using A16 in WisL cells
grown in Medium A (Eagle's Minimum essential medium with
1% non-essential amino acids, 5% fetal calf serum and pen/strep)
in 12-well plates. The drugs were diluted to 1, 2, 5 or 10 μg/ml, and
then incubated with virus (2107 RNA copies, 15 min, room
temperature). Aliquots (200 μl) were added to cell-containing
wells. After 15 min at room temperature, then 45 min at 34 1C,
the cells were washed (3 ) with PBS then Medium A, containing
the respective concentrations of drug. Incubation continued at
34 1C for 24 h. Control wells without virus assessed potential
effects of DMSO or the drugs alone. At 24 h PI, CPE was recorded,
if evident. The cells were frozen and thawed three times to release
particles. They were treated with RNase A (Qiagen) then assayed
by qRT-PCR for RNA content as described (Bochkov et al., 2011).
3.6. Drug testing
Capsid-binding drug tests for C15 in human organ cultures
have been described (Bochkov et al., 2011). For ALI-based tests,
cultures of differentiated human sinus epithelium (HSE) or human
bronchial epithelium (HBE) were grown in 12-well plates for 30
days in ALI medium (1:1 BEGM (Lonza) and DMEM (Mediatech)
with additives, then screened for C15 growth before use (Ashraf
et al., 2013). Successful cultures were gently washed (3 ) with
PBS to remove mucus. Virus samples (21078 RNA copies of
A16 or C15) were incubated with pleconaril (10 μg/ml, 26.24 mM),
BTA-188 (2 μg/ml, 5.43 μM) or W91 (2 μg/ml, 5.63 μM) or DMSO
(controls) in ALI medium (15 min at room temperature) then
inoculated into culture wells at the apical ALI surface. 15 min later
(room temperature) the plates were transferred to 34 1C for 3 h
45 min. For samples harvested at this time, the cells were washed
with PBS (3 ), then lysed in RLT buffer (350 μl, Qiagen). The
remaining cultures were fed basally with ALI medium (1 ml with
drug) and incubation continued (to 24 h at 34 1C). At harvest, the
medium was aspirated from the outer wells and cells were lysed
by RLT buffer. RNA extraction and qRT-PCR were as described
(Bochkov et al., 2011). Virus titer is expressed as RNA copies (log10)
averaged from duplicate qRT-PCR values and n¼2–6. Average
error is indicated for each sample type.
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